Biocytogen to Present 26 Posters and a Booth at AACR 2023
Biocytogen is attending AACR Annual Meeting 2023, held from April 14-19 in Orlando, Florida! For the latest advances in our therapeutic antibody assets and platforms, animal models and service offerings, be sure to stop by at our Booth 723 and visit our 26 posters!
Our posters comprise:
RenMabTM-Based Fully Human Antibody Discovery Platforms
RenNanoTM Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics
Poster Number: LB210
Session: Late-Breaking Research: Immunology 2
Date/Time: April 18, 2023, 9:00 AM – 12:30 PM
Abstract: to be disclosed
Discovery of RenNanoTM-Derived Human Heavy-Chain-Only Antibodies That Cross the Blood-Brain-Barrier
Poster Number: LB211
Session: Late-Breaking Research: Immunology 2
Date/Time: April 18, 2023, 9:00 AM – 12:30 PM
Abstract: to be disclosed
Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived from HLA Transgenic RenMiceTM
Poster Number: 2752
Session: Innovative Assay Technologies
Date/Time: April 17, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/2509
The RenMiceTM HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets
Poster Number: 5320
Session: High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery
Date/Time: April 18, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/5254
Fully Human Monoclonal Antibody Assets
1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity
Poster Number: 6436
Session: Immunotherapy Strategies and Mechanisms
Date/Time: April 19, 2023, 9:00 AM – 12:30 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6990
6B5, An Anti-Human B7-H3 Therapeutic Antibody That Enhances Antibody-Dependent Cellular Cytotoxicity and Inhibits Tumor Growth in B7-H3-Humanized Mice
Poster Number: 1528
Session: Antibody Drug Conjugates
Date/Time: April 17, 2023, 9:00 AM – 12:30 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/2650
7E1, A Novel Blocking Antibody Targeting Human Anti-Mullerian-Hormone-Receptor II (AMHRII), Elicits Potent Anti-Tumor Activity In vivo
Poster Number: 6343
Session: Anticancer Immunotherapeutics
Date/Time: April 19, 2023, 9:00 AM – 12:30 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/4058
BCG008, A Human Siglec-15 Blocking Antibody, Displays Potent Anti-Tumor Activity in Siglec-15-Humanized Mice
Poster Number: 6435
Session: Immunotherapy Strategies and Mechanisms
Date/Time: April 19, 2023, 9:00 AM – 12:30 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6976
D02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice
Poster Number: 1866
Session: Therapeutic Antibodies 1
Date/Time: April 17, 2023, 9:00 AM – 12:30 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3781
RenLite®-derived Fully Human Bispecific ADC Assets
A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy
Poster Number: 2977
Session: Therapeutic Antibodies 3
Date/Time: April 17, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3674
YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy
Poster Number: 2978
Session: Therapeutic Antibodies 3
Date/Time: April 17, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3670
A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity
Poster Number: 6325
Session: Anticancer Immunotherapeutics
Date/Time: April 19, 2023, 9:00 AM – 12:30 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/4039
BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET
Poster Number: LB212
Session: Late-Breaking Research: Immunology 2
Date/Time: April 18, 2023, 9:00 AM – 12:30 PM
Abstract: to be disclosed
Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer
Poster Number: LB216
Session: Late-Breaking Research: Immunology 2
Date/Time: April 18, 2023, 9:00 AM – 12:30 PM
Abstract: to be disclosed
A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy
Poster Number: LB215
Session: Late-Breaking Research: Immunology 2
Date/Time: April 18, 2023, 9:00 AM – 12:30 PM
Abstract: to be disclosed
A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1
Poster Number: LB214
Session: Late-Breaking Research: Immunology 2
Date/Time: April 18, 2023, 9:00 AM – 12:30 PM
Abstract: to be disclosed
Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate
Poster Number: LB213
Session: Late-Breaking Research: Immunology 2
Date/Time: April 18, 2023, 9:00 AM – 12:30 PM
Abstract: to be disclosed
Off-the-Shelf Mouse Models
A Novel Triple Humanized B-hPD-1/hPD-L1/hCCR8 Mouse Model to Evaluate In vivo Efficacy of Combination Therapies
Poster Number: 3233
Session: Combination Immunotherapies 1
Date/Time: April 17, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3126
B-hCD94/hNKG2A Mice Provide a Preclinical Tool for Evaluating Therapeutic Antibodies Targeting Human NKG2A
Poster Number: 3286
Session: Combination Immunotherapies 2
Date/Time: April 17, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/4750
Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution
Poster Number: 5208
Session: Novel Preclinical Models for Cancer Immunotherapy
Date/Time: April 18, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6987
Development of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution
Poster Number: 5207
Session: Novel Preclinical Models for Cancer Immunotherapy
Date/Time: April 18, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6982
Generation of Humanized TREM2 Mice for Preclinical Evaluation of Therapeutics Targeting Tumor-Associated Macrophages
Poster Number: 5209
Session: Novel Preclinical Models for Cancer Immunotherapy
Date/Time: April 18, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6988
Humanized OX40/OX40L Mice as a Tool for Evaluating Novel Therapeutics
Poster Number: 5178
Session: Modifiers of the Tumor Microenvironment
Date/Time: April 18, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3613
In vivo Efficacy Evaluation of Anti-Human VEGFR2 Antibodies in Humanized B-hVEGFR2 Mice
Poster Number: 4592
Session: Advances in Angiogenesis
Date/Time: April 18, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/5493
In vivo Efficacy of an Anti-Human IL11RA Antibody in B-hIL11RA Mice With APAP-Induced Liver Damage
Poster Number: 3993
Session: Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3
Date/Time: April 18, 2023, 9:00 AM – 12:30 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/8652
Novel Humanized CD36 Mouse Model for Therapeutic Studies
Poster Number: 5196
Session: Novel Preclinical Models for Cancer Immunotherapy
Date/Time: April 18, 2023, 1:30 PM – 5:00 PM
Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6977
To schedule a meeting with us, please contact us at BD-Licensing@biocytogen.com.
About AACR Annual Meeting
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNanoTM mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTMlicensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
Biocytogen’s Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn